© Copyright 2004-2018 PharmaInformatic Boomgaarden. All rights reserved.         Site map           Contact         Terms of Use         Imprint        

PharmaInformatic provides
ADME Knowledge Bases
 and Expert Systems
to improve drug discovery
and development.

DGPT 2018:
Our current
research project
(Animal-free toxicity testing)
is presented at
German Pharm-Tox Summit 2018

The company was founded in 2004 and is based in Emden, Germany.

  Get In Contact

    LinkedIn   Twitter

Unsere Technologien
 ersetzen Tierversuche
 in der Medikamenten-Entwickung
und bei toxikologischen Untersuchungen


About two-thirds of drug candidates fail in clinical trials due to lack of efficacy, many as a result of incorrect first-in-human dose or insufficient drug-uptake in human. Pharmaceutical companies use IMPACT-F to evaluate drug-uptake in humans prior to clinical trials.

New technology to evaluate Plasma Protein Binding of compounds by artificial intelligence:

PharmaInformatic is developing a large and comprehensive annotated knowledge base on Plasma Protein Binding of compounds. It now contains more than 17.000 data records taken from more than 2.400 scientific publications. The technology to improve toxicity assessment of compounds and to improve discovery of new drugs will be available for licensing (more).


IMPACT-F:  Prediction of oral bioavailability in humans (drug-uptake)

The expert system IMPACT-F accelerates drug discovery and development: It calculates oral bioavailability of future drugs in humans. The technology is used to optimise lead candidates. Predictions were shown to be much more precise than animal trials: they were as accurate as the common deviation between individual humans taking part in the same clinical trial. Read our current research results on bioavailability of drugs.


PACT-F:  Largest knowledge base on bioavailability of drugs worldwide

PharmaInformatic has developed PACT-F, which is the largest knowledge base on bioavailability worldwide. It contains 8296 records, which describe in detail the results of clinical trials in humans and preclinical trials in animals, see content of PACT-F. Since 2005 the detailed results and conditions of more than 5000 scientific publications concerning the bioavailability of drugs have been evaluated and integrated into the database (more).

Oral bioavailability is one of the most important properties of a drug. If a new drug candidate has low or no oral bioavailability, further drug development is stopped. Low oral bioavailability in clinical trials is a major reason for drug candidates failing to reach the market. Efficacy issues have been identified as the main reason why clinical trials fail.

Our research replaces animal tests
A large number of animal trials is carried out every day to select and optimise drug compounds. New effective drugs must be taken up into the human body ("oral bioavailability") otherwise itís a waste of time, money and resources. The expert system IMPACT-F evaluates oral drug uptake significantly more reliably than animal tests. Pharmaceutical companies use the technology to optimise the development of novel drugs (see customers testimonials).